Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 5;102(12):2015–2020. doi: 10.3324/haematol.2016.158857

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2017 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 3. — Effect of lenalidomide on S100A9 and tumor necrosis factor-α production in peripheral blood mononuclear cells from patients with non-del(5q) myelodysplastic syndrome. (A) Frozen peripheral blood mononuclear cells (PBMC) from lower-risk MDS patients (n=7) were treated with 1 μM lenalidomide for 24 h, before analysis of supernatant S100A9 concentration by ELISA. Results are expressed relative to untreated cells. (B) PBMC from lower-risk MDS patients (n=7) were treated with 1 μM lenalidomide 30 min prior to addition of lipopolysaccharide (LPS) (1 μg/mL): 24 h after stimulation, TNFα ELISA was performed on the supernatants. Results are expressed as a percentage relative to LPS treatment alone. *mean P≤0.05.